S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in

NASDAQ:ORGO - Organogenesis Stock Price, Forecast & News

$5.29
-0.02 (-0.38 %)
(As of 01/20/2020 04:00 PM ET)
Today's Range
$5.25
Now: $5.29
$5.44
50-Day Range
$4.44
MA: $4.92
$5.32
52-Week Range
$3.56
Now: $5.29
$55.23
Volume61,064 shs
Average Volume79,626 shs
Market Capitalization$501.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORGO
CUSIPN/A
CIKN/A
Phone781-575-0775

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$193.45 million
Book Value$0.52 per share

Profitability

Miscellaneous

Employees700
Market Cap$501.17 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.


Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc (NASDAQ:ORGO) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The company earned $64.27 million during the quarter, compared to analysts' expectations of $64 million. View Organogenesis' Earnings History.

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Organogenesis.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis issued an update on its fourth quarter 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $72.6-74.6 million, compared to the consensus revenue estimate of $70.41 million.

What price target have analysts set for ORGO?

7 brokerages have issued 1-year price objectives for Organogenesis' stock. Their forecasts range from $9.00 to $12.00. On average, they anticipate Organogenesis' stock price to reach $10.29 in the next year. This suggests a possible upside of 94.4% from the stock's current price. View Analyst Price Targets for Organogenesis.

What is the consensus analysts' recommendation for Organogenesis?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Organogenesis.

Has Organogenesis been receiving favorable news coverage?

News articles about ORGO stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Organogenesis earned a news impact score of 0.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Organogenesis.

Are investors shorting Organogenesis?

Organogenesis saw a drop in short interest in December. As of December 31st, there was short interest totalling 76,300 shares, a drop of 9.7% from the December 15th total of 84,500 shares. Based on an average trading volume of 139,000 shares, the short-interest ratio is currently 0.5 days. Currently, 0.7% of the shares of the stock are sold short. View Organogenesis' Current Options Chain.

Who are some of Organogenesis' key competitors?

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Opko Health (OPK), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Aptinyx (APTX), OrganiGram (OGI), vTv Therapeutics (VTVT), Main Street Capital (MAIN), Altria Group (MO), Uber Technologies (UBER) and AzurRx BioPharma (AZRX).

Who are Organogenesis' key executives?

Organogenesis' management team includes the folowing people:
  • Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 64)
  • Mr. Timothy M. Cunningham, Chief Financial Officer (Age 57)
  • Mr. Patrick Bilbo, Chief Operating Officer (Age 57)
  • Ms. Lori H. Freedman, VP & Gen. Counsel (Age 52)
  • Angelyn Lowe, Director of Corp. Communications

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $5.29.

How big of a company is Organogenesis?

Organogenesis has a market capitalization of $501.17 million and generates $193.45 million in revenue each year. Organogenesis employs 700 workers across the globe.View Additional Information About Organogenesis.

What is Organogenesis' official website?

The official website for Organogenesis is http://organogenesis.com/.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at 781-575-0775 or via email at [email protected]


MarketBeat Community Rating for Organogenesis (NASDAQ ORGO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Organogenesis and other stocks. Vote "Outperform" if you believe ORGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel